Colorectal cancer DNA vaccine - Cellectis/Karolinska Institute

Drug Profile

Colorectal cancer DNA vaccine - Cellectis/Karolinska Institute

Alternative Names: Carcinoembryonic antigen DNA vaccine - Cellectis/Karolinska Institute; tetwtCEA DNA

Latest Information Update: 22 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cyto Pulse Sciences; Karolinska Institute
  • Developer Cellectis; Karolinska Institute
  • Class Cancer vaccines; DNA vaccines; Gene therapies
  • Mechanism of Action Gene transference; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Colorectal cancer

Most Recent Events

  • 22 Sep 2015 Colorectal cancer DNA vaccine is still in phase I/II trials for Colorectal cancer in Sweden
  • 06 Nov 2009 Preclinical trials in Colorectal cancer in Sweden (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top